STOCKS TELEGRAPH

Tag: GLPG

  • Galapagos NV (GLPG) Stock High in Premarket. Here’s the Reason.

    Galapagos NV (GLPG) is a leading biotherapeutics company engaged in development and commercialization of therapies using small molecules. The pipeline project of the company includes filgotinib used in treating rheumatoid arthritis, ulcerative colitis and other diseases. GLPG1690 is tested against idiopathic pulmonary fibrosis and NOVESA for systemic sclerosis.

    The price of GLPG stock during the regular trading on January 26, 2022 was $53.32 with a slight decrease of 0.04%. At last check in the premarket on January 27, 2022, the stock sharply inclined by 12.08%.

    GLPG: Events and Happenings

    On 26 January 2022, GLPG reported about the approval of its Subscription Right Plan 2022 by the company’s supervisory board. The plan created up to 1,000,000 subscription rights which have eight years exercise term.

    On January 18, 2022, GLPG reported about the grant of approval for the marketing of filgotinib by the Medicines and Healthcare products Regulatory Agency. On January 6 2022, GLPG reported that the Company’s Executives presented at 40th Annual J.P. Morgan Healthcare Conference held on January 10-13, 2022.

    On December 3, 2021, GLPG reported an incline in its share capital due to its subscription right exercises. The company issued 22,600 ordinary shares for a total capital rise of €0.57 million. On November 22, 2021, GLPG reported about the closure of enrolment during its Phase 2 clinical studies of MANGROVE.

    On November 15, 2021, GLPG reported about the grant of approval for the marketing of filgotinib by the European Commission.

    GLPG: Key Financials

    On November 4, 2021, GLPG reported its financial results for the quarter ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    Collaboration revenue in Q3 2021 was €58.5 million compared to €127.5 million in the same period of 2020.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was €64.6 million or €0.99 compared to €81.9 million or €1.25 in the same period in 2020.

    Conclusion

    GLPG stock down performed from the past six months period by 11% due to sluggish economic development in pandemic conditions. The current premarket increase in stock price is the result of creation of new subscription right plan by the company. The investors and experts are eager to see the company blooming.

  • Galapagos NV (GLPG) Stock Trending Lower Despite Successful Topline Results from GLPG3667 and GLPG 3970 Studies

    Galapagos NV (GLPG) stock prices were down a marginal 1.79% as of the market closing on July 14th, 2021, bringing the price per share down to USD$65.80. Subsequent premarket fluctuations have seen the stock fall by 11.14%, bringing it down to USD$58.47.

    GLPG3667

    July 14th, 2021 saw the company announce positive topline results from the evaluation of GLPG3667, a proprietary TYK2 compound. The randomized, placebo-controlled, double-blind Phase 1b study had a total of 31 patients enrolled, each with a diagnosis ranging from moderate to severe plaque psoriasis. Patients were randomized in a 1:1:1 ratio and were administered a daily oral dose of GLPG3667 or a placebo over the course of four weeks. The main objectives of the study were to evaluate the safety and tolerability of the treatment, as well as signs indicating clinical activity.

    Success of the Study

    The treatment was found to be well tolerated during the course of the trial, barring one patient in the low dose group having interrupted the study for one day on account of the exacerbation of psoriasis. Any treatment related adverse events were mild in nature and transient, with no deaths or serious adverse events being reported. By Week 4, 40% of patients in the high dose group had a PASI 50 response, which is indicative of a minimum 50% improvement in PASI from baseline.

    GLPG3970

    Concurrently, the company announced the success of topline results from three patient studies for GLPG3970. The study evaluated the proprietary salt inducible kinase 2/3 inhibitor. The studies were randomized, placebo-controlled, double blind, with a Phase 1b study in patients with moderate to severe psoriasis. Two Phase 2a studies were also conducted in patients with moderate to severely active UC and RA.

    Continued Success

    With the treatment being administered orally once-daily for a period of 6 weeks, the main objectives were to evaluate the safety and tolerability of GLPG3970, as well as early signs of biologic and clinical effect. The treatment was generally safe and well tolerated across all three studies. No deaths or serious adverse events were reported, while the majority of treatment emergent adverse events were mild to moderate in nature.

    Future Outlook for GLPG

    Armed with the success of its various studies, GLPG is poised to capitalize on the opportunities presented to it as it further develops its flagship treatments. The company is keen to push for the accelerated development and eventual commercialization of its pipeline of products. Investors are hopeful that the proliferation of the treatment will result in sustained and significant increases in shareholder value.